BioCentury
ARTICLE | Company News

GTC Biotherapeutics, Lundbeck deal

July 19, 2010 7:00 AM UTC

H. Lundbeck returned to GTC U.S. rights for hematology drug ATryn. The recombinant antithrombin is marketed in the U.S. to prevent peri-operative and peri-partum thromboembolic events in patients wit...